Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, ...

Midwives and family physicians are essential to support mothers facing hypogalactia and maintain WHO-recommended exclusive ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, ...

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...

A large study suggests taking progesterone before pregnancy — not just after conception — may help reduce the risk for ...

Weekly intramuscular injections of rotigotine extended-release microspheres are linked to significant symptom improvement in ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

Patients with presyncope and those with syncope in the ED have similar 30‑day serious cardiac outcomes, although patients ...

A smartphone application for muscle relaxation significantly reduces migraine-related disability in patients visiting the ...